PLK1 and cancer: Indeed, the above findings provide a theoretical basis for further structural modification of 4-benzyloxy-1-(2-(aryl/alkylamino)pyridin-4-yl)-1H-pyrazole-3-carboxamide derivatives as PLK1 inhibitors, and compound 15 is a promising lead for new therapeutics targeting cancer due to its strong kinase selectivity profile.